Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DVA Stock Forecast 2025-2026
$135.79
Current Price
$10.32B
Market Cap
Buy 1
Hold 8
Sell 1
Wall St Analyst Ratings
Distance to DVA Price Targets
+37.0%
To High Target of $186.00
+15.6%
To Median Target of $157.00
+6.8%
To Low Target of $145.00
DVA Price Momentum
-0.2%
1 Week Change
-6.8%
1 Month Change
-3.2%
1 Year Change
-9.2%
Year-to-Date Change
-24.4%
From 52W High of $179.60
+3.1%
From 52W Low of $131.76
📊 TOP ANALYST CALLS
Did DVA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if DaVita is one of their latest high-conviction picks.
Latest DVA Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, DVA has a neutral consensus with a median price target of $157.00 (ranging from $145.00 to $186.00). The overall analyst rating is Buy (6.2/10). Currently trading at $135.79, the median forecast implies a 15.6% upside. This outlook is supported by 1 Buy, 8 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Kevin Fischbeck at B of A Securities, suggesting a 6.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DVA Analyst Ratings
1
Buy
8
Hold
1
Sell
DVA Price Target Range
Low
$145.00
Average
$157.00
High
$186.00
Current: $135.79
Latest DVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $164.00 |
| Feb 18, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $169.00 |
| Oct 31, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $164.00 |
| Oct 7, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $175.00 |
| Aug 20, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $165.00 |
| Aug 8, 2024 | UBS | Andrew Mok | Buy | Maintains | $175.00 |
| Aug 7, 2024 | B of A Securities | Kevin Fischbeck | Underperform | Maintains | $145.00 |
| Jul 24, 2024 | TD Cowen | Gary Taylor | Hold | Maintains | $150.00 |
| May 15, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $150.00 |
| May 6, 2024 | Barclays | Andrew Mok | Equal-Weight | Maintains | $150.00 |
| Mar 6, 2024 | Barclays | Sarah James | Equal-Weight | Initiates | $133.00 |
| Feb 20, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $135.00 |
| Feb 15, 2024 | UBS | Andrew Mok | Buy | Maintains | $145.00 |
| Feb 14, 2024 | UBS | Andrew Mok | Buy | Maintains | $134.00 |
| Feb 14, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $130.00 |
| Nov 17, 2023 | UBS | Andrew Mok | Buy | Maintains | $113.00 |
| Oct 11, 2023 | Truist Securities | David Macdonald | Hold | Maintains | $104.00 |
| Aug 7, 2023 | UBS | Andrew Mok | Buy | Upgrade | $142.00 |
| Jul 13, 2023 | Truist Securities | David Macdonald | Hold | Maintains | $115.00 |
| May 15, 2023 | Bernstein | Lisa Bedell Clive | Market Perform | Maintains | $100.00 |
DaVita Inc. (DVA) Competitors
The following stocks are similar to DaVita based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DaVita Inc. (DVA) Financial Data
DaVita Inc. has a market capitalization of $10.32B with a P/E ratio of 13.6x. The company generates $12.97B in trailing twelve-month revenue with a 6.6% profit margin.
Revenue growth is +5.0% quarter-over-quarter, while maintaining an operating margin of +13.4% and return on equity of +54.8%.
Valuation Metrics
Market Cap
$10.32B
Enterprise Value
$24.04B
P/E Ratio
13.6x
PEG Ratio
12.1x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
+5.0%
Gross Margin
+30.5%
Operating Margin
+13.4%
Net Margin
+6.6%
EPS Growth
-32.0%
Financial Health
Cash/Price Ratio
+5.0%
Current Ratio
1.3x
Debt/Equity
742.2x
ROE
+54.8%
ROA
+7.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
DaVita Inc. (DVA) Business Model
About DaVita Inc.
What They Do
Provides kidney care and dialysis services.
Business Model
DaVita generates revenue primarily through its dialysis services, which include hemodialysis and peritoneal dialysis, catering to patients with chronic kidney failure and end-stage renal disease. The company operates a network of dialysis centers and also offers ancillary services such as laboratory testing and outpatient management, enhancing its service offerings and revenue streams.
Additional Information
DaVita is recognized for its clinical excellence and innovative approaches to patient care, addressing the increasing demand for specialized kidney treatment. The company plays a vital role in the healthcare sector by improving patient outcomes and ensuring accessible care solutions across the United States.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
76,000
CEO
Mr. Javier J. Rodriguez
Country
United States
IPO Year
1995
Website
www.davita.comDaVita Inc. (DVA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know
DaVita HealthCare (DVA) reached $137.84 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
Jun 16, 2025
By Zacks Equity Research
Tale of the Tape
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jun 16, 2025
By Zacks Equity Research
Tale of the Tape
DaVita HealthCare (DVA) Down 3.4% Since Last Earnings Report: Can It Rebound?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 11, 2025
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
DaVita HealthCare (DVA) closed at $137.84, up 1.26% from the previous trading day.
Why It Matters
DaVita's stock price increase signals positive market sentiment and potential growth, which can attract investors and impact future trading activity.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors should avoid focusing solely on metrics like dividend yield or price ratios and instead consider a broader analysis to identify potential opportunities.
Why It Matters
Focusing solely on one metric can lead to missed investment opportunities, emphasizing the need for a comprehensive analysis of multiple factors for better decision-making.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
DaVita responded to recent updates from CMMI regarding its Kidney Care Choices Model, as stated by Misha Palecek, chief transformation officer.
Why It Matters
DaVita's response to CMMI updates on the KCC Model may signal changes in reimbursement policies, impacting its financial outlook and potentially influencing stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Premium research service offers Zacks Style Scores, aiding value, growth, and momentum investors in identifying strong stocks.
Why It Matters
The Zacks Style Scores highlight strong stock options, enhancing stock-picking strategies for various investor types, potentially leading to better investment decisions and returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
DaVita expands internationally with new clinics in Brazil, Ecuador, Chile, and Colombia. The stock has a 10% FCF yield, decreasing share count, and revenue growth expected above inflation.
Why It Matters
DaVita's international expansion and strong free cash flow yield signal robust growth potential. Decreasing share count enhances value, while revenue growth above inflation reflects solid market positioning.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
DaVita Inc. is offering $750 million in senior notes due 2033. Proceeds will repay credit facility borrowings, cover related expenses, and support general corporate purposes, including stock repurchases.
Why It Matters
DaVita's $750 million senior notes offering signals financial restructuring, potentially reducing debt costs and enhancing liquidity, which could positively impact stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DVA Stock
What is DaVita Inc.'s (DVA) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, DaVita Inc. (DVA) has a median price target of $157.00. The highest price target is $186.00 and the lowest is $145.00.
Is DVA stock a good investment in 2025?
According to current analyst ratings, DVA has 1 Buy ratings, 8 Hold ratings, and 1 Sell ratings. The stock is currently trading at $135.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DVA stock?
Wall Street analysts predict DVA stock could reach $157.00 in the next 12 months. This represents a 15.6% increase from the current price of $135.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is DaVita Inc.'s business model?
DaVita generates revenue primarily through its dialysis services, which include hemodialysis and peritoneal dialysis, catering to patients with chronic kidney failure and end-stage renal disease. The company operates a network of dialysis centers and also offers ancillary services such as laboratory testing and outpatient management, enhancing its service offerings and revenue streams.
What is the highest forecasted price for DVA DaVita Inc.?
The highest price target for DVA is $186.00 from at , which represents a 37.0% increase from the current price of $135.79.
What is the lowest forecasted price for DVA DaVita Inc.?
The lowest price target for DVA is $145.00 from Kevin Fischbeck at B of A Securities, which represents a 6.8% increase from the current price of $135.79.
What is the overall DVA consensus from analysts for DaVita Inc.?
The overall analyst consensus for DVA is neutral. Out of 10 Wall Street analysts, 1 rate it as Buy, 8 as Hold, and 1 as Sell, with a median price target of $157.00.
How accurate are DVA stock price projections?
Stock price projections, including those for DaVita Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 7:50 PM UTC